Search

Displaying results 1451 - 1460 of 1613 in total
  1. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the ...

  2. Drug

    Posaconazole

    go.drugbank.com/drugs/DB01263
    ApprovedInvestigationalVet approved

    Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.

    Categories: Metabolic Side Effects of Drugs and Substances
  3. Drug

    MRx-4DP0004

    go.drugbank.com/drugs/DB15751
    Investigational

    MRx-4DP0004 is a lyophilised formulation of the Bifidobacterium breve strain of commensal bacteria. It is a live biotherapeutic derived from the microbiota of a healthy human infant.

  4. Drug

    ZEN-012

    go.drugbank.com/drugs/DB06042
    Experimental

    ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms of action: tubulin and topoisomerase II inhibition. ZEN-012 also expresses additional modes of action such as pro-apoptotic and anti...

  5. Drug

    Selamectin

    go.drugbank.com/drugs/DB11459
    ExperimentalVet approved

    It also removes 2 types of lungworm in cats and one type of lungworm in dogs. It is distributed by Zoetis, a former Pfizer subsidiary. It is structurally related to ivermectin and milbemycin.

  6. Drug

    Davunetide

    go.drugbank.com/drugs/DB12613
    Investigational

    Davunetide is the first drug to improve memory performance by impacting the mechanisms that lead to physical damage in the brain caused by neurofibrillary tangles, one of the two established pathological

  7. Drug

    Andexanet alfa

    go.drugbank.com/drugs/DB14562
    Approved

    The amino acid residue modification from serine to alanine in the binding site of the catalytic domain allows more effective binding to FXa inhibitors and deters the andexanet alfa from converting prothrombin

  8. Drug

    Irofulven

    go.drugbank.com/drugs/DB05786
    Investigational

    Food and Drug Administration (FDA) after demonstrating promise against one of the most deadly cancers.

  9. Drug

    TGAAC94

    go.drugbank.com/drugs/DB06175
    Investigational

    In 2007, one patient participating in the clinical trial died and the trial was placed on clinical hold by the FDA.

  10. Drug

    Vinflunine

    go.drugbank.com/drugs/DB11641
    ApprovedInvestigational

    Having an incidence of 429,700 new cases per year worldwide, urothelial carcinoma of the bladder is one of the most common malignancies that mostly affects individuals aged 50–79 years [A32626].